Ken Griffin Heron Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,200 shares of HRTX stock, worth $45,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,200

Previous 38,500 4.42%

Holding current value

$45,024

Previous $134,000 41.04%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.73 - $3.67 $1.82 Million - $3.85 Million	1,050,280 Added 194.04%	1,591,547 $3.17 Million
Q2 2024 Aug 14, 2024	SELL	$2.32 - $3.86 $74,634 - $124,176	-32,170 Reduced 5.61%	541,267 $1.89 Million
Q1 2024 May 15, 2024	BUY	$1.71 - $3.06 $327,735 - $586,473	191,658 Added 50.2%	573,437 $1.59 Million
Q4 2023 Feb 14, 2024	BUY	$0.54 - $1.82 $200,550 - $675,927	371,389 Added 3574.49%	381,779 $649,000
Q3 2023 Nov 14, 2023	SELL	$0.97 - $1.8 $412,832 - $766,081	-425,601 Reduced 97.62%	10,390 $10,000
Q2 2023 Aug 14, 2023	SELL	$1.11 - $2.88 $681,326 - $1.77 Million	-613,808 Reduced 58.47%	435,991 $505,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.25 $670,521 - $1.44 Million	-444,054 Reduced 29.73%	1,049,799 $1.59 Million
Q4 2022 Feb 14, 2023	BUY	$2.25 - $4.67 $992,603 - $2.06 Million	441,157 Added 41.91%	1,493,853 $3.73 Million
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $2.54 Million - $5.14 Million	956,712 Added 996.74%	1,052,696 $4.44 Million
Q2 2022 Aug 15, 2022	SELL	$2.3 - $6.29 $265,852 - $727,048	-115,588 Reduced 54.63%	95,984 $268,000
Q1 2022 May 16, 2022	SELL	$4.63 - $9.94 $6.86 Million - $14.7 Million	-1,481,347 Reduced 87.5%	211,572 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$8.35 - $12.6 $13 Million - $19.6 Million	1,552,390 Added 1104.68%	1,692,919 $15.5 Million
Q3 2021 Nov 15, 2021	BUY	$10.13 - $15.0 $792,905 - $1.17 Million	78,273 Added 125.73%	140,529 $1.5 Million
Q2 2021 Aug 16, 2021	SELL	$13.27 - $18.48 $5.84 Million - $8.14 Million	-440,222 Reduced 87.61%	62,256 $966,000
Q1 2021 May 17, 2021	SELL	$14.49 - $20.72 $2.3 Million - $3.28 Million	-158,502 Reduced 23.98%	502,478 $8.15 Million
Q4 2020 Feb 16, 2021	BUY	$14.61 - $22.14 $7.88 Million - $11.9 Million	539,643 Added 444.75%	660,980 $14 Million
Q3 2020 Nov 16, 2020	SELL	$13.67 - $17.77 $3.91 Million - $5.09 Million	-286,337 Reduced 70.24%	121,337 $1.8 Million
Q2 2020 Aug 14, 2020	SELL	$10.89 - $21.47 $12 Million - $23.6 Million	-1,101,232 Reduced 72.98%	407,674 $6 Million
Q1 2020 May 15, 2020	SELL	$10.23 - $24.56 $3.37 Million - $8.1 Million	-329,744 Reduced 17.93%	1,508,906 $17.7 Million
Q4 2019 Feb 14, 2020	BUY	$17.42 - $26.61 $3.43 Million - $5.23 Million	196,650 Added 11.98%	1,838,650 $43.2 Million
Q3 2019 Nov 14, 2019	BUY	$16.36 - $21.39 $5.31 Million - $6.94 Million	324,462 Added 24.63%	1,642,000 $30.4 Million
Q2 2019 Aug 14, 2019	BUY	$16.93 - $26.22 $6.23 Million - $9.65 Million	367,914 Added 38.74%	1,317,538 $24.5 Million
Q1 2019 May 15, 2019	SELL	$23.15 - $28.34 $39.2 Million - $48 Million	-1,692,479 Reduced 64.06%	949,624 $0
Q4 2018 Feb 14, 2019	BUY	$22.03 - $32.01 $16.7 Million - $24.2 Million	756,523 Added 40.12%	2,642,103 $68.5 Million
Q3 2018 Nov 13, 2018	BUY	$30.0 - $40.85 $18.8 Million - $25.5 Million	625,420 Added 49.63%	1,885,580 $0
Q2 2018 Aug 10, 2018	BUY	$26.4 - $42.0 $8.7 Million - $13.8 Million	329,647 Added 35.43%	1,260,160 $0
Q1 2018 May 11, 2018	SELL	$18.43 - $28.8 $12.2 Million - $19 Million	-659,351 Reduced 41.47%	930,513 $25.7 Million
Q4 2017 Feb 09, 2018	BUY	$14.8 - $18.85 $20.8 Million - $26.5 Million	1,404,870 Added 759.41%	1,589,864 $28.8 Million
Q3 2017 Nov 09, 2017	BUY	$14.65 - $16.85 $2.71 Million - $3.12 Million	184,994	184,994 $2.99 Million

Others Institutions Holding HRTX

# of Institutions

180

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $133M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account